<DOC>
	<DOCNO>NCT02448069</DOCNO>
	<brief_summary>Background : Our prior work combination argatroban + recombinant tissue plasminogen activator ( rt-PA ) ( ARTSS-1 : Phase IIa low-dose safety study ; n=65 ARTSS-2 : Phase IIb randomize low high-dose study ; n=90 ) , demonstrate safety two drug deliver concomitantly recanalization rate great historical control . Further , interim analysis neurological outcome 75 patient randomized Phase IIb trial , demonstrate signal efficacy compare control ( rt-PA alone ) patient . However , rt-PA fails reperfuse brain patient large thrombus , prompt several recent randomize clinical trial demonstrate intra-arterial therapy ( IA ) follow rt-PA substantially improve outcome patient distal carotid proximal middle cerebral artery occlusion . As result , rt-PA + IA become new standard-of-care many patient large arterial occlusion treat ARTSS-1 2 . Therefore , study necessary explore feasibility safety add Argatroban acute ischemic stroke patient also receive rt-PA follow IA . Primary Objective : To demonstrate feasibility safety treat stroke patient Argatroban undergo usual thrombolysis care ( intravenous rt-PA follow IA ) . Secondary Objectives : 1 . Assess rate ultra-early recanalization commencement IA ; 2 . Assess completeness pattern reperfusion obtain IA ; 3 ) Assess clinical outcome</brief_summary>
	<brief_title>Safety Feasibility Argatroban , Tissue Plasminogen Activator Intra-arterial Therapy Stroke</brief_title>
	<detailed_description>Design : Prospective , single-arm , open-label , feasibility safety Phase IIa study . Study Population : 10 total ischemic stroke patient treat rt-PA ( 0-3 hour 0-4.5 hour accord site 's local standard ) IA ; age 18 year old ; proximal ( intracranial ) artery occlusion image CT-angiogram ( CTA ) . Treatment : All patient receive standard-of-care intravenous rt-PA ( 0.9 mg/kg ; maximum 90 mg ) IA . Before end 1 hour rt-PA infusion , 3.0 mcg/kg/min continuous infusion Argatroban , precede 100 mcg/kg bolus administer 3-5 minute . Infusion titrate achieve aPTT 2.25 time baseline ( exceed 10 mcg/kg/min ) maximum 12 hour . Assessments : 1 . Baseline : History physical exam , vital sign , CBC , liver function test , PT/INR , PTT , non-contrast head CT , CT-Angiogram , NIHSS , mRS , concomitant medication . Laboratory result must report study drug administration . 2 . 0-24 hour : Vital sign , aPTT ( schedule 2 , 6 , 12 hour ) , NIHSS ( 24-hours ) , conventional angiography part usual care intra-arterial therapy . Repeat parenchymal brain imaging ( non-contrast head CT MRI ) 24 hour rt-PA bolus . Laboratory test work ( baseline ) . 3 . Day 7/Discharge ( whichever occurs first ) : Vital sign , mRS , NIHSS 4 . Day 90 : mRS ( obtain certify rater ) .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Brain Ischemia</mesh_term>
	<mesh_term>Cerebral Infarction</mesh_term>
	<mesh_term>Plasminogen</mesh_term>
	<mesh_term>Tissue Plasminogen Activator</mesh_term>
	<mesh_term>Argatroban</mesh_term>
	<criteria>Disabling Ischemic stroke symptom onset &lt; 3 hour treat IV rtPA local standards* . &lt; /= 4.5 hour accord local standard care . Symptoms must distinguish another ischemic event syncope , seizure , migraine , subarachnoid hemorrhage hypoglycemia . If patient report awaken event , time onset consider last time patient ( witness patient 's condition ) consider herself/himself normal . Patients meet local , institutional criterion undergo emergent Endovascular Therapy ( IntraArterial ) include : 1 . IAT must able begin 6hours stroke onset last see well . 2 . CTAngiogram confirmation intraarterial occlusion follow location : terminal ICA , MCA ( M1 M2 territory ) , PCA , distal vertebral basilar artery . 3 . ASPECTS score noncontrast head CT must &gt; /= 6 . 4 . IAT must able begin within 90 minute qualify CT scan . Age &gt; /= 18 . Females childbearing potential must negative pregnancy test prior administration trial medication . Signed ( write ) inform consent patient patient 's legal representative and/or guardian . Evidence intracranial hemorrhage ( ICH ) baseline CT scan diagnosis nonvascular cause neurologic deficit . NIHSS Level Consciousness score ( 1a ) &gt; /= 2 . Preexisting disability mRS &gt; 2 . Any evidence clinically significant bleeding , know coagulopathy . INR &gt; 1.5 . Patients elevate aPTT great upper limit normal ( test repeat investigator suspect falsely elevate value collection tube completely fill ) . Patients currently , within previous 24 hour , oral direct thrombin inhibitor ( i.e. , dabigatran ) , factor 10a inhibitor ( i.e. , rivaroxaban , apixaban ) , longacting anticoagulant . Heparin flush require IV line . Line flush saline . Any history intracranial hemorrhage , know ateriovenousmalformation unsecured cerebral aneurysm . Significant bleed episode [ e.g . gastrointestinal ( GI ) urinary tract ] within 3 week study enrollment . Major surgery serious trauma last 2 week . Patients arterial puncture noncompressible site , biopsy parenchymal organ , lumbar puncture within last 2 week . Previous stroke , myocardial infarction ( MI ) , post myocardial infarction pericarditis , intracranial surgery , significant head trauma within 3 month . Uncontrolled hypertension ( SBP &gt; 185 mmHg DBP &gt; 110 mmHg ) respond intravenous antihypertensive agent . Surgical intervention ( reason ) anticipate within next 48 hour . Known history clinically significant hepatic dysfunction liver disease include current history alcohol abuse . Abnormal blood glucose &lt; 50 mg/dL ( 2.7 mmol/L ) . History primary metastatic brain tumor . Current platelet count &lt; 100,000/mm3 . Life expectancy &lt; 3 month . Patients , judgment investigator , need concomitant ( i.e. , Argatroban infusion ) anticoagulants Argatroban , include form heparin , UFH , LMWH , defibrinogenating agent , dextran , direct thrombin inhibitor thrombolytic agent , GPIIb/IIIa inhibitor warfarin . [ *Caveat : However , judgment investigator patient need anticoagulated , defer 48 hour , could include . ] Currently participate participate investigational drug device study within 30 day first dose study medication . Known hypersensitivity Argatroban agent . Additional exclusion criterion patient present 34.5 hour : 1 . Age &gt; 80 2 . Currently take oral anticoagulant ( regardless INR ) 3 . A history stroke diabetes . 4 . NIHSS &gt; 25 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>